Navigating Treatment Selection in R/R Follicular Lymphoma

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, outline key considerations for treatment selection in relapsed/refractory follicular lymphoma, particularly in the second-line setting. Nastoupil emphasizes the importance of prior response duration, tumor burden, and patient comorbidities when individualizing therapy. Mehta highlights how an expanding therapeutic landscape requires balancing efficacy, toxicity, and patient-specific goals when selecting among available options.